When combined with anti‐PD‐1 and anti‐CTLA‐4, the nanodisc vaccine led to complete tumor regression in ≈88% of mice bearing MC‐38 tumors and ≈90% of mice bearing B16F10 tumors, compared to only ≈25% and ≈38% of mice having complete tumor regression after treatment with free CpG plus peptide neoantigen.97 The same group also reported delivering immunogenic chemotherapeutics98, 99, 100, 101 using the same type of nanodisc. Here, CTLA4 is linked to neoplasm.